Scynexis Secures Up to $214 Million BARDA Cost-Share Award to Advance SCY-247

Scynexis entered into a cost-share BARDA Contract to fund development of SCY-247, a second-generation fungerp antifungal. The award provides up to $214 million in non-dilutive support, including an $18.5 million base period starting in September 2026 to advance oral and IV SCY-247 into Phase 2 for…